Global viral hepatitis and retrovirus diagnostic tests market expected to surpass US $3,335 million by 2019, says Technavio

Renewable energy

 

This market research report segments the global viral hepatitis and retrovirus diagnostic tests market by geography and includes regions like the Americas, APAC, and EMEA. The report also includes an analysis on the key vendors such as Abbott Diagnostics, Alere, Chembio, DiaSorin, and Roche Diagnostics.

Technavio’s market research analysts estimate the global viral hepatitis and retrovirus diagnostic tests market to grow at a CAGR of around 10% between 2015 and 2019. Fcators attributed to this market’s growth are increasing awareness of diagnostic tests, technological advancements and product innovations. The Americas dominate the global market for viral hepatitis and retrovirus diagnostic tests, occupying 44%of the total market share. Much of this region’s growth comes from the advent of insurance programs like Medicaid and the high prevalence of chronic and infectious diseases such as hepatitis A, B, and C.

The new market research report from Technavio provides a breakdown and analysis of the viral hepatitis and retrovirus diagnostic tests segments by technology.

“POC diagnostic tests have gained significance in this market as these tests provide quick results for instant treatment decisions. They reduce hospital stays and backlogs. These tests are also used for HIV self-testing, and are an efficient diagnostic tool for the hesitant patients. Moreover, biomarkers are another personalized test tools gaining grounds in the market. These are proteins, genes, hormones that detect the presence or absence of disease,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.

Nucleic acid test (NAT) is increasingly being used for HIV and Hepatitis detection. NAT is a specific molecular technique that works on the amplification of targeted regions of viral RNA or DNA, hence speedily detects the virus in blood samples. It provides better blood safety by minimising the risk of transfusion-transmitted infections. Currently, NAT is practiced by 33 countries for screening HIV, and in 27 countries for hepatitis.

The leading vendors in the global viral hepatitis and retrovirus diagnostic tests market are Abbott Diagnostics, Alere, Chembio, DiaSorin, and Roche Diagnostics. Competition in this market is intense due to the augmented availability of advanced IVD assays and instruments from numerous vendors. Large vendors in this market focus more on increasing their POC product portfolio for HIV and hepatitis detection as it helps them to gain traction in this market.

A more detailed analysis is available in the Technavio report, Global Viral Hepatitis and Retrovirus Diagnostic Tests Market 2015-2019.

We can customize reports by other regions and specific segments upon request.

Other Related Reports: